LifeSci Capital Rates Immix Biopharma (IMMX) buy

LifeSci Capital reaffirms its 'buy' rating on Immix Biopharma with a $19 price target, a 91.73% upside from the current price.

By TradeTexts Research Desk · Published Jun 18, 2026, 3:02 AM EDT · Updated Jun 24, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

LifeSci Capital rated Immix Biopharma, Inc. ($IMMX) "buy" with a $19 price target on June 17, 2026.

Since the rating, $IMMX is up 10.0% after 1 week, up 12.3% after 1 month and down 12.6% to date (from the $9.13 close on Jun 17, 2026).

IMMX Immix Biopharma, Inc.

$7.98 +46.96% year to date

Daily close · Oct 16, 2026

Key Points

LifeSci Capital reiterated its 'buy' rating on Immix Biopharma, setting a price target of $19 on June 17, 2026.
LifeSci Capital's $19 price target implies 91.73% upside from Immix Biopharma, Inc.'s ($IMMX) current $9.91 share price.
Shares of Immix Biopharma, trading on NasdaqCM under the ticker IMMX, are priced at $8.74, with a market cap of about $650 million.
Analysts from firms like HC Wainwright & Co. and Mizuho also maintain 'buy' ratings with varying price targets.

Get $IMMX trade alerts by text

We text you when insiders, Congress or big funds trade $IMMX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Immix Biopharma, Inc. alert may contain errors. Disclosures

LifeSci Capital has reiterated its 'buy' rating on Immix Biopharma, Inc. (NasdaqCM: IMMX), setting a price target of $19 as of June 17, 2026. Immix Biopharma is currently trading at $8.74 per share.

Analysts Set New Price Targets

On June 17, 2026, LifeSci Capital initiated coverage on Immix Biopharma with a 'buy' rating and a $19 price target. HC Wainwright & Co. maintained its 'buy' rating on May 22, 2026, with a target of $20. Mizuho also maintained a 'buy' rating on March 30, 2026, with a $15 target. The consensus from analysts is a 'buy' recommendation, with a mean target price of $18.46 across five opinions.

Other Institutional Activity in Immix Biopharma

Janus Henderson Group PLC added 880,434 shares of Immix Biopharma, bringing its total to 4,802,002 shares worth about $43.7 million. Saturn V Capital Management LP also increased its position by 694,416 shares, ending with 3,693,585 shares valued at approximately $33.6 million. Eventide Asset Management, LLC held steady with 2,549,019 shares worth roughly $23.2 million. Vanguard Capital Management LLC acquired 1,787,994 shares, while Millennium Management LLC added 90,422 shares to hold a total of 1,750,200 shares valued at $15.9 million.

Immix Biopharma, Inc. Stock Down 20.7%

Shares of Immix Biopharma are trading near $8.74. The company has a market cap of around $650 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock's 52-week range is between $1.94 and $11.61. It has a 50-day moving average of $9.23 and a 200-day moving average of $6.26. Immix Biopharma's current ratio stands at 8.76, indicating strong liquidity.

12-month forecast

$IMMX price target

Immix Biopharma, Inc. daily closes and this analyst's $19 target. Not advice.

Insider Buying and Selling at Immix Biopharma, Inc.

Several insiders made purchases of Immix Biopharma shares on May 22, 2026. Helen Adams bought a total of 18,750 shares, while Jane Buchan acquired 12,500 shares. Magda Marquet and Jason Hsu each purchased 6,250 shares, and Yekaterina Chudnovsky also bought 12,500 shares. These transactions were not part of any pre-arranged trading plans.

About Immix Biopharma

Immix Biopharma, Inc. is a biotechnology company based in Los Angeles, California. It focuses on developing treatments for light chain amyloidosis and immune-mediated diseases. The company's lead product, NXC-201, is designed for patients with relapsed or refractory AL amyloidosis. Founded in 2012, it operates with a small team of 21 employees under the leadership of CEO Dr. Ilya Rachman.

Bottom Line

LifeSci Capital's reiteration of a 'buy' rating with a $19 target underscores confidence in Immix Biopharma's potential. Investors often track analyst ratings to gauge institutional sentiment. It's important to remember that these ratings are based on projections and past performance, and actual results may vary.